Compare VanEck Rare Earth/Strategic Metals (REMX) vs UnitedHealth Group Inc (UNH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Rare Earth/Strategic Metals vs UnitedHealth Group Inc — how do they compare? VanEck Rare Earth/Strategic Metals trades at $71.1, while UnitedHealth Group Inc trades at $431.6 (market cap $396.27B). The key difference: UnitedHealth Group Inc pays a 2.13% dividend while VanEck Rare Earth/Strategic Metals pays none, and UnitedHealth Group Inc is trading nearer its 52-week high, VanEck Rare Earth/Strategic Metals nearer its low. Which is the better fit depends on your goals.
| REMX | UNH | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $109.53 | $436.35 |
52-Week Low | $49.22 | $237.77 |
Market Cap | — | $396.27B |
Enterprise Value | — | $442.96B |
Dividend Yield | — | 2.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
REMX, the VanEck Rare Earth and Strategic Metals ETF, trades at $69.85, down 3.88% amid bearish technical signals. The ETF faces selling pressure with 13 bearish moving average signals against zero bullish, though oscillators show some buying opportunity with RSI readings in oversold territory. Recent news highlights ongoing geopolitical tensions around rare earth supply chains, with China's export controls and US efforts to secure critical minerals driving volatility in the sector.
The ETF offers exposure to 38 global rare earth companies but carries high volatility (~50% annualized) and significant China concentration risk. While strategic metals demand remains strong for technology and defense applications, REMX is best suited as a satellite holding for aggressive portfolios due to its specialized nature and geopolitical sensitivities.
UnitedHealth Group (UNH) trades at $431.31, up 2.32% today, with a bullish technical outlook and strong analyst support. The stock shows consistent earnings beats, with Q2 2026 EPS of $6.38 surpassing expectations by 29%, and maintains robust cash flow from operations of $19.70 billion in 2025. Recent news highlights strategic moves to reduce pediatric prior authorizations, aiming to improve care access and operational efficiency.
The outlook remains positive with an 82.69% analyst buy rating and a consensus price target of $476.50, implying 10.5% upside. Key risks include regulatory scrutiny, as seen in Massachusetts' $100 million Medicaid fraud lawsuit filed May 29, 2026, and margin pressure from rising medical costs. Long-term growth is supported by aging demographics and digital health investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Rare Earth/Strategic Metals
REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.
Read more on REMX →About UnitedHealth Group Inc
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Read more on UNH →
